Abstract 1682P
Background
Prostate cancer (PC) presents a significant health challenge in Africa, especially in regions like Nigeria with limited access to care. Despite medical advancements, PC treatment affects patients beyond their physical health, impacting their quality of life (QoL) and financial toxicity (FT) due to high treatment costs and inadequate insurance coverage. Patient-reported outcomes are often overlooked in African PC research, creating knowledge gaps that need to be addressed.
Methods
This descriptive cross-sectional study aimed to assess patient-reported outcomes among male PC patients at Lagos University Teaching Hospital (LUTH) and the NSIA-LUTH Cancer Centre (NLCC). Data collection involved interviewer-based structured questionnaires that inculcated QoL (FACT-P), psychosocial distress (PHQ-4), and FT (FACIT-COST). Analysis was done with RStudio, with a P-value set at <0.05 for statistical significance. Ethical approval was obtained.
Results
This study examined 200 prostate cancer patients at LUTH. Participants were primarily aged 61–70; most are married with tertiary education, and the majority are retired. Comorbidities, particularly hypertension (32.0%) and diabetes mellitus (22.5%), are prevalent. Notable findings include the impact of age, employment status, and comorbidities on QoL and FT. ECOG scores, cancer stage, and comorbidities significantly influence psychological distress levels. Associations between QoL, financial toxicity, and psychosocial distress underscore the complex interplay between these factors. No significant link was found between QoL and FT.
Conclusions
This study sheds light on the challenges faced by PC patients at LUTH, highlighting the complex interplay of factors. Economic challenges included limited health insurance coverage and financial strain. Early detection and intervention are crucial, given the distribution of cancer stages and the prevalence of comorbidities among patients. FT emerges as a significant issue, impacting patients' QoL and psychosocial well-being. The lack of significant associations with health insurance coverage suggests the need for comprehensive healthcare reforms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R. O. Jimoh.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1656TiP - The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT)
Presenter: Sarah Howlett
Session: Poster session 11
1658TiP - The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT)
Presenter: Minal Padden-Modi
Session: Poster session 11
1659TiP - A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer
Presenter: Mark Stein
Session: Poster session 11
1660TiP - First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Raanan Berger
Session: Poster session 11
1661TiP - SEGNO: An exploratory study of the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer
Presenter: Haichao Huang
Session: Poster session 11
1662TiP - HARMONY: A phase II study of niraparib (N)/abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa)
Presenter: Qian Qin
Session: Poster session 11
1664P - Early integration of psycho-oncology in cancer care: A model of care from a quaternary care government hospital in India and its patient related outcomes
Presenter: Niharika Bisht
Session: Poster session 11
1665P - Awareness of illness, psychological difficulties, and resources across life ages in early stage and metastatic cancer patients
Presenter: Raffaela Sartori
Session: Poster session 11